Clinical trials
Terminated Movement Disorders trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2023 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 23 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Drexel University College of Medicine | 5 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 4 |
| Sun Pharmaceutical Industries, Inc. | 3 |
| Oregon Health and Science University | 2 |
| Britannia Pharmaceuticals Ltd. | 1 |
| Fondation Ophtalmologique Adolphe de Rothschild | 1 |
| GE Healthcare | 1 |
| Insel Gruppe AG, University Hospital Bern | 1 |
| Merck Sharp & Dohme LLC | 1 |
| Michael J. Fox Foundation for Parkinson's Research | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Movement Disorders | 23 |
| Parkinson Disease | 11 |
| Neurodegenerative Diseases | 9 |
| Amyotrophic Lateral Sclerosis | 5 |
| Central Nervous System Diseases | 4 |
| Dyskinesias | 4 |
| Motor Neuron Disease | 4 |
| Dystonia | 3 |
| Dystonic Disorders | 3 |
| Parkinsonian Disorders | 3 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.